novo nordisk obesity - Search News

Order byBest matchMost fresh

Novo Nordisk Inks A Major Obesity Deal

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

· 12h · on MSN

· 1d · on MSN

Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal

BioPharma Dive · 20h

Novo to work with Septerna in hunt for oral obesity drugs

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments.

· 12h

Ignore The Noise - Novo Nordisk Is A Clear Buy

STAT · 1d

Novo Nordisk strikes deal with Septerna to develop obesity pills

pharmaphorum1d

Novo makes fresh obesity play with $2.2bn Septerna deal

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage candidates developed by Septerna.

Why patients are being forced to switch to a 2nd-choice obesity drug

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of insurance-imposed limits that disrupt treatment.